Literature DB >> 24090752

Performance evaluation of affinity ligands for depletion of abundant plasma proteins.

Majlinda Kullolli1, Jonathan Warren, Maria Arampatzidou, Sharon J Pitteri.   

Abstract

Human plasma is a commonly used diagnostic fluid in clinical chemistry. In-depth plasma proteomic analysis is performed to search for disease biomarkers, however the large dynamic range of protein abundance in plasma presents a substantial analytical challenge. Removal of abundant plasma proteins using antibody capture approaches is a common and attractive means to reduce sample complexity and to aid the analysis of lower abundance proteins of interest. A novel class of heavy chain camelid-derived affinity ligands produced in Saccharomyces cerevisiae, has recently been developed as an alternative to antibody-based depletion methods. Here, we evaluate the performance characteristics of these ligands for removal of high abundance plasma proteins. Affinity ligands were tested for the removal of 14 abundant human plasma proteins. The performance characteristics were evaluated by gel-electrophoresis and LC-MS/MS of the bound and flow-through fractions. The capacity of a 5.6mL column was found to be 125μL of plasma. Replicate analysis demonstrated high column reproducibility and linearity, efficient removal of abundant proteins, and enrichment of lower abundance proteins observed after depletion. The novel class of affinity ligands provides an attractive alternative to traditional antibody-based immunodepletion methods.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affinity ligands; Immunoaffinity/immunodepletion alternative; Ligand affinity; Plasma proteomics; Protein depletion

Mesh:

Substances:

Year:  2013        PMID: 24090752     DOI: 10.1016/j.jchromb.2013.09.008

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

Review 1.  Proteomics and autoimmune kidney disease.

Authors:  Brad H Rovin; Jon B Klein
Journal:  Clin Immunol       Date:  2015-05-13       Impact factor: 3.969

2.  Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine.

Authors:  Szymon Filip; Konstantinos Vougas; Jerome Zoidakis; Agnieszka Latosinska; William Mullen; Goce Spasovski; Harald Mischak; Antonia Vlahou; Joachim Jankowski
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

3.  Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.

Authors:  Maria Frantzi; Akshay Bhat; Agnieszka Latosinska
Journal:  Clin Transl Med       Date:  2014-03-29

4.  Proteomic profiling of whole-saliva reveals correlation between Burning Mouth Syndrome and the neurotrophin signaling pathway.

Authors:  Guy Krief; Yaron Haviv; Omer Deutsch; Naama Keshet; Galit Almoznino; Batia Zacks; Aaron Palmon; Doron J Aframian
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

Review 5.  Review of Liquid Chromatography-Mass Spectrometry-Based Proteomic Analyses of Body Fluids to Diagnose Infectious Diseases.

Authors:  Hayoung Lee; Seung Il Kim
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

6.  Proteomic sample preparation for blast wound characterization.

Authors:  Brett A Chromy; Angela Eldridge; Jonathan A Forsberg; Trevor S Brown; Benjamin C Kirkup; Eric Elster; Paul Luciw
Journal:  Proteome Sci       Date:  2014-02-14       Impact factor: 2.480

7.  Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.

Authors:  Christine Y Yeh; Ravali Adusumilli; Majlinda Kullolli; Parag Mallick; Esther M John; Sharon J Pitteri
Journal:  Biomark Res       Date:  2017-10-17

8.  Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.

Authors:  Sarah M Totten; Ravali Adusumilli; Majlinda Kullolli; Cheylene Tanimoto; James D Brooks; Parag Mallick; Sharon J Pitteri
Journal:  Sci Rep       Date:  2018-04-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.